A number of clinical programs are in development featuring our tetravalent bispecific ICE® (innate cell engager) molecules based on the ROCK® (Redirected Optimized Cell Killing) platform, and have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Acimtamig (AFM13) is a first-in-class ICE® molecule that has the potential to deliver clinically meaningful benefits to patients with CD30+ lymphomas.1

AFM24 is an EGFR-binding ICE® molecule that kills EGFR-expressing tumors, and through ADCC and ADCP, holds promise to treat patients with a more acceptable safety profile compared with current advanced treatments, while remaining immune to the challenge of resistance.2

AFM28 is an ICE® that binds to CD123 on leukemic cells and is being developed for patients with relapsed and refractory acute myeloid leukemia (AML).

Innate Cell Engagers ICE®

Pre-Clinical
Phase 1
Phase 2
Additional Information

Active Clinical Trials

Disease Target CD30

Acimtamig (AFM13) + ADOPTIVE NK CELLS: LuminICE-203

CD30-positive lymphoma
Phase 2
Enrolling, Collaboration with
Disease Target EGFR

AFM24 + ANTI-PD-L1: AFM24-102

Multiple EGFR+ solid tumors
Phase 1/2a
Ongoing
Disease Target CD123

AFM28 MONOTHERAPY: AFM28-101

Acute Myeloid Leukemia (AML)
Phase 1
Ongoing

Preclinical ICE®

Disease Target FRα

AFM32

Solid tumors
Pre-Clinical
Disease Target Undisclosed

Novel ICE®

Multiple indications (not disclosed)
Pre-Clinical
Disease Target Undisclosed

Novel ICE® - GENENTECH

Multiple indications (not disclosed)
Pre-Clinical
Partnered with
CD = cluster of differentation
EGFR = epidermal growth factor receptor
FRα = Folate receptor alpha
ICE® = innate cell engager
NK = natural killer
PD-L1 = programmed death ligand 1
Affimed programs
Partnered programs


See all Publications and Posters

Expanded Access Policy

Affimed does not currently have an expanded access program for our investigational products. Expanded access, also known as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational drug for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

We are focused on enrolling and conducting the clinical trials necessary to bring innovative, safe, and effective products to patients as quickly as possible. Participation in one of our clinical trials is the only way to access Affimed’s investigational products at this time. We encourage patients and healthcare providers interested in our investigational products to learn more about our ongoing studies by visiting Affimed Clinical Studies on our website. For more information, please contact us at info@affimed.com

ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; EGFR=epidermal growth factor receptor.

References: 1. Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024-4031. 2. Reusch U, Damrat M, Wingert S, et al. AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; June 22-24, 2020; Virtual. Poster 5659.